<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339128</url>
  </required_header>
  <id_info>
    <org_study_id>3030-202-002</org_study_id>
    <secondary_id>2017-003770-14</secondary_id>
    <nct_id>NCT03339128</nct_id>
  </id_info>
  <brief_title>Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children</brief_title>
  <official_title>Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to explore the therapeutic effect of eluxadoline in&#xD;
      treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years&#xD;
      of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D,&#xD;
      and to evaluate the safety and tolerability of eluxadoline in pediatric participants with&#xD;
      IBS-D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Anticipated">August 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in stool consistency averaged over the 4-week Treatment Period</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool consistency for daily daytime and nighttime stool consistency scores</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Stool consistency will be assessed using the Pediatric Bristol Stool Form Scale (p-BSFS) on a range from 1 (Hard Lumps) to 7 (Watery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for daytime, nighttime, and 24-hour abdominal pain scores</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Abdominal Pain is scored on a five-point ordinal scale, with 0 meaning no pain, and 4 meaning a lot of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for daytime, nighttime, and 24-hour bowel movement frequency</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Change from baseline in the number of bowel movements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for daytime, nighttime, and 24 hour urgency-free days</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Change from baseline in the number urgency free days in a week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline for daytime, nighttime, and 24 hour number of fecal incontinence-free days</measure>
    <time_frame>Baseline (2 Weeks prior to randomization) to Week 4</time_frame>
    <description>Change from baseline in the number of fecal incontinence-free days in a week.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Eluxadoline 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 25mg, oral administration, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eluxadoline 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 50mg, oral administration, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eluxadoline 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 100mg, oral administration, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-matched placebo, oral administration, twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eluxadoline</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Eluxadoline 100mg</arm_group_label>
    <arm_group_label>Eluxadoline 25mg</arm_group_label>
    <arm_group_label>Eluxadoline 50mg</arm_group_label>
    <other_name>Viberzi, Truberzi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must provide written or verbal informed assent and the parent/guardian/LAR&#xD;
             must provide written informed consent before the initiation of any study-specific&#xD;
             procedures.&#xD;
&#xD;
          -  Participant is a male or female outpatient, 6 to 17 years of age inclusive, at the&#xD;
             time the participant provides assent for the study and parent/guardian/LAR has&#xD;
             provided signed consent.&#xD;
&#xD;
          -  Participant is able to read and understand the assessments in the eDiary. If the&#xD;
             participant is 6 to 11 years of age and does not meet this criterion, the&#xD;
             interviewer-administered version of the eDiary must be used and the&#xD;
             parent/guardian/LAR or caregiver who will be administering the&#xD;
             interviewer-administered version of the eDiary must be able to read and understand the&#xD;
             assessments in the eDiary and must undergo training.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum pregnancy&#xD;
             test at Visit 1 (screening) and a negative urine pregnancy test at Visit 3&#xD;
             (randomization) prior to dosing.&#xD;
&#xD;
          -  Female participants who have had their first menstrual period and are sexually active&#xD;
             must agree to use a reliable form of contraception. Reliable contraception is defined&#xD;
             as:&#xD;
&#xD;
               -  Hormonal contraception (eg, oral contraceptive, contraceptive implant, or&#xD;
                  injectable hormonal contraceptive).&#xD;
&#xD;
               -  Double-barrier method (eg, condom plus intrauterine device, diaphragm plus&#xD;
                  spermicide).&#xD;
&#xD;
          -  Participant has a diagnosis of IBS-D as defined by the modified Rome IV&#xD;
             child/adolescent criteria: Must include all of the following:&#xD;
&#xD;
             -- Abdominal pain at least 4 days per month over at least 2 months associated with one&#xD;
             or more of the following:&#xD;
&#xD;
               -  Related to defecation&#xD;
&#xD;
               -  A change in frequency of stool&#xD;
&#xD;
               -  A change in form (appearance) of stool&#xD;
&#xD;
                    -  After appropriate evaluation, the symptoms cannot be fully explained by&#xD;
                       another medical condition.&#xD;
&#xD;
                    -  Participant has predominantly diarrheal stool symptoms defined as Bristol&#xD;
                       stool types 6 or 7 for more than 25% of bowel movements and Bristol stool&#xD;
                       types 1 or 2 for less than 25% of bowel movements that occur in the absence&#xD;
                       of laxative.&#xD;
&#xD;
               -  All criteria fulfilled for at least 2 months prior to Visit 1 (screening).&#xD;
&#xD;
          -  Participant has been compliant with the eDiary by completing both the morning and&#xD;
             evening assessments for at least 8 out of the 14 days immediately preceding Visit 3&#xD;
             (randomization).&#xD;
&#xD;
          -  Participant has an average daytime abdominal pain scoreless than or equal to 2.0 over&#xD;
             the 2 weeks prior to randomization.&#xD;
&#xD;
          -  Participant has at least 1 daytime bowel movement with a consistency of Type 6 or Type&#xD;
             7 on the pediatric Bristol Stool Form Scale (p-BSFS) on at least 2 days per week&#xD;
             during the 2 weeks prior to randomization that occurs in the absence of laxatives.&#xD;
&#xD;
          -  Participant has no clinically significant findings on a physical examination, vital&#xD;
             sign assessment, electrocardiogram (ECG), and clinical laboratory tests (clinical&#xD;
             chemistry panel, liver biochemical tests, complete blood count, urine drug screen,&#xD;
             urinalysis) after providing informed assent and after written consent is obtained, but&#xD;
             before receiving the first dose of study treatment. (A central laboratory will be used&#xD;
             to evaluate all urine [except urine pregnancy tests] and blood samples and will&#xD;
             utilize reference ranges specific to a patient's age and gender. ECGs will be&#xD;
             performed and electronically transmitted to a central ECG laboratory for analysis by a&#xD;
             pediatric cardiologist in accordance with the instructions provided by the central ECG&#xD;
             laboratory. The Investigator will determine if a particular finding is clinically&#xD;
             significant. [In making this determination, the Investigator will consider whether the&#xD;
             particular finding could represent a condition that would exclude the participant from&#xD;
             the study, could represent a safety concern if the participant participates in the&#xD;
             study, or could confound the study-specific assessments of safety or efficacy.])&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy).&#xD;
&#xD;
          -  Participant has had any of the following surgeries:&#xD;
&#xD;
               -  Any abdominal surgery within the 3 months prior to Screening; or&#xD;
&#xD;
               -  A history of major gastric, hepatic, pancreatic, or intestinal surgery. (Note:&#xD;
                  appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery&#xD;
                  are allowed. For the purposes of this study, laparoscopic surgeries without&#xD;
                  complication are considered minor and non-exclusionary, provided the condition&#xD;
                  for which the surgery was performed was not exclusionary.)&#xD;
&#xD;
          -  Participant has a history of chronic or severe constipation or sequelae from&#xD;
             constipation, or known or suspected mechanical GI obstruction or pseudo obstruction.&#xD;
&#xD;
          -  Participant has a history or current diagnosis of constipation with encopresis.&#xD;
&#xD;
          -  Participant meets the child/adolescent Rome IV criteria of IBS with constipation, IBS&#xD;
             with constipation and diarrhea (mixed), unspecified IBS, or functional constipation.&#xD;
&#xD;
          -  Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI&#xD;
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic&#xD;
             colitis, or impaired intestinal circulation.&#xD;
&#xD;
          -  Participant has a documented history of hepatic impairment as defined by Child-Pugh&#xD;
             Classification Grade A, B or C.&#xD;
&#xD;
          -  Participant has a history or current diagnosis of inflammatory or immune-mediated&#xD;
             lower GI disorders including inflammatory bowel disease (eg, Crohn's disease,&#xD;
             ulcerative colitis, microscopic colitis). Crohn's disease affecting the upper GI tract&#xD;
             would also be exclusionary.&#xD;
&#xD;
          -  Participant has celiac disease, or a positive serological test for celiac disease and&#xD;
             the condition has not been ruled out by endoscopic biopsy.&#xD;
&#xD;
          -  Participant has any congenital and/or acquired malabsorption syndrome (eg,&#xD;
             Shwachman-Diamond syndrome).&#xD;
&#xD;
          -  Participant has a history of a microbiologically documented (ie, stool culture or&#xD;
             medical history) GI infection within 3 months prior to Screening.&#xD;
&#xD;
          -  Participant has a known lactose or fructose intolerance that is associated with&#xD;
             diarrhea, abdominal pain or discomfort, and that could confound assessments in the&#xD;
             study.&#xD;
&#xD;
          -  Participant has a history of diverticulitis within 3 months prior to Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HealthStar Research of Hot Springs PLLC /ID# 234609</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas /ID# 238070</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212-4187</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindred Medical Institute, LLC /ID# 237368</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VVCRD Research /ID# 234606</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials LLC /ID# 234630</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center /ID# 237802</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ctr for Gastro Disorders /ID# 236961</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research /ID# 237401</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sunrise Research Institute /ID# 237382</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>South Miami Medical &amp; Research Group Inc. /ID# 234655</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valencia Medical &amp; Research Center /ID# 234672</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Center, Inc. /ID# 236514</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Treken Primary Care /ID# 234646</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30315</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Ctr Digestive, US /ID# 237575</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 236343</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Children's Digestive Health /ID# 235388</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health /ID# 235400</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Michael W. Simon, MD, PSC /ID# 236517</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virgo Carter Pediatrics /ID# 234519</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology /ID# 238057</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Celen Medical Group Corp /ID# 234922</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UH Cleveland Medical Center /ID# 237918</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company /ID# 237672</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - Main /ID# 234313</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians, Inc. /ID# 236436</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cook Children's Med. Center /ID# 237537</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital /ID# 238304</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Research Institute /ID# 236933</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's /ID# 237984</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHATSv.Ivan Rilski /ID# 235399</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Plovdiv /ID# 235450</name>
      <address>
        <city>Plovdiv</city>
        <zip>4001</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev /ID# 237808</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical center 1 Sevlievo /ID# 237473</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveta Marina /ID# 237833</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edmonton Clinic Health Academy (ECHA) /ID# 234917</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital /ID# 238061</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eszak-Kozep-budai Centrum, Uj Szent Janos Korhaz /ID# 236993</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 237341</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vita Verum Medical Bt. /ID# 234321</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesu /ID# 238184</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AORN Santobono-Pausilipon /ID# 235653</name>
      <address>
        <city>Naples</city>
        <zip>80129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum /ID# 237117</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital /ID# 237315</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki /ID# 237438</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Sp. z o.o. /ID# 236347</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-539</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM /ID# 237269</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-635</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 234311</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Copertnicus Podmiot Leczniczy Sp. z o.o. /ID# 235656</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korczowski Bartosz Gabinet Lekarski /ID# 234683</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-302</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset /ID# 236755</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manchester University NHS Foundation Trust /ID# 234663</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust /ID# 237273</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trusts /ID# 236305</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://childibsd.com</url>
    <description>Research study website to register and learn more about this study.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome with Diarrhea</keyword>
  <keyword>IBSD</keyword>
  <keyword>IBS-D</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

